<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of small bowel neoplasms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of small bowel neoplasms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of small bowel neoplasms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James C Cusack, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Overman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hiroko Kunitake, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A variety of tumors, both malignant and benign, arise within the small intestine. Malignant tumors include adenocarcinomas, neuroendocrine (carcinoid) tumors, sarcomas, and lymphomas, while benign lesions include adenomas, leiomyomas, lipomas, and hamartomas.</p><p>The treatment of the various types of neoplasms that arise in the small bowel will be reviewed here. The epidemiology, clinical manifestations, diagnosis, and staging of small bowel tumors are discussed separately. (See  <a class="medical medical_review" href="/d/html/2517.html" rel="external">"Epidemiology, clinical features, and types of small bowel neoplasms"</a> and  <a class="medical medical_review" href="/d/html/2516.html" rel="external">"Diagnosis and staging of small bowel neoplasms"</a>.)</p><p class="headingAnchor" id="H3502830091"><span class="h1">ADENOCARCINOMA</span></p><p class="headingAnchor" id="H3"><span class="h2">Locoregional disease</span></p><p class="headingAnchor" id="H4"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Localized invasive adenocarcinomas of the small bowel are best managed with wide segmental surgical resection. Resection of the primary and investing mesentery achieves surgical clearance of both the primary and the regional nodes at risk for metastases, and provides important staging information that impacts decisions regarding the need for adjuvant therapy (see below). However, resection of adequate mesentery may be limited by the proximity of the nodes or tumor to the superior mesenteric artery. The optimal number of regional lymph nodes needed for adequate staging is debated [<a href="#rid1">1-4</a>], but guidelines from the National Comprehensive Cancer Network (NCCN) recommend that a goal for all small bowel adenocarcinoma resections should be the retrieval of at least eight regional nodes [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2173824854"><span class="h4">Duodenal tumors</span><span class="headingEndMark"> — </span>Pancreaticoduodenectomy is required for tumors involving the second portion of the duodenum and for those invading into any portion of the ampulla or pancreas. For tumors involving the first, third, and fourth portions of the duodenum, there is debate regarding the need for pancreaticoduodenectomy compared with wide local excision. Those favoring pancreaticoduodenectomy note the more radical clearance of the tumor bed and regional lymph nodes [<a href="#rid6">6-8</a>]. However, the majority of data, though limited by sample size, demonstrate similar outcomes between pancreaticoduodenectomy and wide local excision:</p><p class="bulletIndent1"><span class="glyph">●</span>Unlike pancreatic cancers, which diffusely infiltrate into the surrounding soft tissues, the extension of duodenal adenocarcinomas into adjacent tissues is usually a more localized process, and tumor-free resection margins may be obtained without resection of adjacent organs and soft tissues. Because a negative margin is critical to a curative procedure, the margin status of the resected specimen must be confirmed on frozen-section and subsequent permanent histologic sections [<a href="#rid6">6,9,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of retrospective studies have not shown a survival benefit for pancreaticoduodenectomy as compared with segmental resection [<a href="#rid11">11-16</a>]. The largest series, from the Mayo Clinic, analyzed 68 patients with duodenal adenocarcinoma; 50 underwent radical surgery (pancreaticoduodenectomy or total pancreatectomy) while 18 had limited surgery (segmental duodenal resection or transduodenal excision) [<a href="#rid17">17</a>]. There was no significant difference between the two groups in terms of five-year overall survival (52 percent versus 61 percent), rate of margin-negative resections, or local recurrence rates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 1161 cases of small bowel adenocarcinoma derived from the Surveillance, Epidemiology, and End Results (SEER) database, the outcomes of 865 patients undergoing radical resection were compared with those of 746 who had simple resection [<a href="#rid18">18</a>]. Radical resection was not associated with improved disease-specific or overall survival, even when the analysis was controlled for confounding factors such as more poorly differentiated and larger tumors, but also a larger number of retrieved lymph nodes in the radical resection group.</p><p></p><p>These observations support the view that segmental resection provides an equivalent survival benefit to that of a more extensive resection for lesions in the distal third or fourth portions of the duodenum, and satisfies the principle of en bloc resection without the morbidity of a pancreaticoduodenectomy. As long as a margin-negative resection can be obtained, segmental resection is preferred over pancreaticoduodenectomy for tumors arising in the third and fourth portions of the duodenum to the left of the superior mesenteric artery.</p><p>For noninvasive in situ (Tis,  (<a class="graphic graphic_table graphicRef110785" href="/d/graphic/110785.html" rel="external">table 1</a>)) lesions, endoscopic resection is a reasonable option. T1 lesions may be considered for endoscopic resection, though the exact rate of recurrence has not been well defined, and support for this approach is based upon only a small single institution retrospective series [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H384145877"><span class="h4">Jejunoileal tumors</span><span class="headingEndMark"> — </span>Adenocarcinomas involving the jejunum or proximal ileum should be treated by wide excision of the malignancy and surrounding tissues at risk for contiguous spread. Tumors of the distal ileum require resection of the ileocolic artery and associated regional lymph nodes.</p><p class="headingAnchor" id="H5"><span class="h3">Outcomes</span><span class="headingEndMark"> — </span>At the time of diagnosis, between 65 and 76 percent of patients with a small bowel adenocarcinoma are without distant metastases and potentially resectable; approximately one-half of these have regional nodal involvement [<a href="#rid20">20,21</a>]. In general, five-year survival rates for small bowel adenocarcinoma are worse than for similarly staged colon cancers, particularly for node-positive disease [<a href="#rid1">1,22-24</a>]. Nodal involvement is one of the strongest predictors of long-term survival [<a href="#rid1">1,2,16,22,25-27</a>]. In a systematic review, five-year overall survival rates for individuals with node-positive and node-negative disease were 21 versus 65 percent [<a href="#rid16">16</a>].</p><p>Five-year disease-specific survival by stage  (<a class="graphic graphic_table graphicRef110785" href="/d/graphic/110785.html" rel="external">table 1</a>) [<a href="#rid28">28</a>] for 4995 cases of small bowel adenocarcinoma reported to the National Cancer Database (NCDB) between 1985 and 1995 were as follows [<a href="#rid22">22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage I – 65 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage II – 48 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III – 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IV – 4 percent</p><p></p><p>However, in a Surveillance, Epidemiology, and End Results (SEER) registry analysis of 1991 cases with stage I, II, or III disease from 1988 to 2005, five-year disease-specific survival was higher: stage I, 85 percent; stage II, 69 percent; and stage III, 50 percent [<a href="#rid2">2</a>]. In addition, this analysis showed that the number of lymph nodes evaluated was a strong prognostic factor with markedly improved five-year disease-specific survival in patients with ≥8 lymph nodes evaluated: stage I, 95 percent; stage II, 83 percent; and stage III, 56 percent. These data, in conjunction with those from two additional studies evaluating the SEER registry, suggest that a portion of stage I or II small bowel adenocarcinomas are undergoing inadequate lymph node evaluation, and consequently being understaged (and undertreated) [<a href="#rid2">2,3,29</a>]. This appears to be particularly true for duodenal adenocarcinomas; in one study, the assessment of eight or more lymph nodes resulted in an improvement in disease-specific survival of 33 and 50 percent for patients with stage I and II disease, respectively [<a href="#rid1">1</a>].</p><p>Site also impacts prognosis. Five-year disease-specific survival rates are worse for duodenal primaries than for tumors arising in the jejunum or ileum in most [<a href="#rid2">2,21,22,29-32</a>] but not all [<a href="#rid20">20,24,33</a>] series.</p><p>Besides tumor site, and the presence of nodal and distant metastases, other poor prognostic factors include positive resection margins, lymphovascular involvement, T4 tumor stage, extent of nodal disease, and poorly differentiated histology [<a href="#rid2">2,9,10,20-22,25,31,33-38</a>]. Positive resection margins increase the rate of local failure, while lymph node involvement and transmural invasion of the bowel wall correlate with distant failure [<a href="#rid15">15,17</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Adjuvant therapy</span><span class="headingEndMark"> — </span>Optimal perioperative therapy is not defined. We prefer that eligible patients with resected stage I to III small bowel adenocarcinoma be enrolled in clinical trials testing the benefit of adjuvant therapy, if possible. One such trial, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02502370%3Fterm%3DBALLAD%26draw%3D2%26rank%3D2&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPz%2FYmGBYRwYKdne7XmTNZl84ymLtiPsbPvz9Pfas0QBM4yz3Ff2AJ7Vmsj7U9QXjOc5BkZEeirTokBk5P30uE2&amp;TOPIC_ID=2509" target="_blank">the BALLAD trial</a>, is recruiting internationally, and a similar trial is underway in Japan [<a href="#rid39">39</a>].</p><p>If a clinical trial is not available or participation is not feasible, we suggest adjuvant chemotherapy for all patients with lymph node-positive, completely resected small bowel adenocarcinomas, in part extrapolating from published data in resected node-positive colon cancer, where routine use of adjuvant chemotherapy significantly improves survival. As with node-positive colon cancer, we suggest use of an oxaliplatin-based regimen. Options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>  (<a class="graphic graphic_table graphicRef96117" href="/d/graphic/96117.html" rel="external">table 2</a>), largely based upon its activity in metastatic small bowel adenocarcinoma. (See <a class="local">'Systemic therapy'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">Oxaliplatin</a> plus short-term infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) and <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (ie, FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 3</a>)), extrapolating from benefit in patients with node-positive colon cancer. (See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer"</a>.)</p><p></p><p>For those with completely resected T3 or T4 node-negative resected small bowel adenocarcinomas, observation or six months of adjuvant chemotherapy are both acceptable options, and we base our decision-making on clinicopathologic features, molecular prognostic factors such as deficient mismatch repair (dMMR), and patient preference, taking the following issues into account:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with high-risk features (eg, T4 primary, few lymph nodes examined, tumor perforation) could be offered adjuvant chemotherapy, although as with stage II colon cancer, there is no evidence that these features predict for responsiveness to adjuvant therapy. (See  <a class="medical medical_review" href="/d/html/15256.html" rel="external">"Adjuvant therapy for resected stage II colon cancer", section on 'Clinicopathologic features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extrapolating data from colon cancer, patients whose tumors have dMMR may have a better outcome than those with proficient mismatch repair, and guidelines from the NCCN use this feature to recommend observation alone after resection of a T3 or T4 node-negative small bowel adenocarcinoma [<a href="#rid5">5</a>]. If adjuvant chemotherapy is chosen in this setting, an oxaliplatin-containing regimen should be used, and not just a fluoropyrimidine. (See  <a class="medical medical_review" href="/d/html/15256.html" rel="external">"Adjuvant therapy for resected stage II colon cancer", section on 'Prevalence of MMR enzyme deficiency'</a>.)</p><p></p><p>If adjuvant chemotherapy is chosen for node-negative disease, we suggest a fluoropyrimidine alone (<a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, leucovorin-modulated FU), as long as the tumor has proficient mismatch repair. In the setting of dMMR, an oxaliplatin-containing regimen would be chosen rather than a fluoropyrimidine alone. (See  <a class="medical medical_review" href="/d/html/15256.html" rel="external">"Adjuvant therapy for resected stage II colon cancer", section on 'Should an oxaliplatin-containing regimen be used?'</a> and  <a class="medical medical_review" href="/d/html/15256.html" rel="external">"Adjuvant therapy for resected stage II colon cancer", section on 'High-risk tumors and benefit of oxaliplatin'</a>.)</p><p>Given the higher risk of local failure for patients with node-positive duodenal adenocarcinomas [<a href="#rid15">15,34,40</a>] and those with a positive resection margin, the addition of fluoropyrimidine-based chemoradiotherapy to a course of systemic oxaliplatin-based chemotherapy is reasonable in these situations, although whether this improves survival is not established. (See <a class="local">'Chemoradiotherapy for duodenal primaries'</a> below.)</p><p>Importantly, for complete staging, all patients should undergo contrast-enhanced computed tomography (CT) of the abdomen/pelvis and chest prior to initiation of adjuvant therapy.</p><p class="headingAnchor" id="H659277803"><span class="h4">Rationale</span><span class="headingEndMark"> — </span>There is a paucity of data addressing the benefit of adjuvant therapy (chemotherapy, radiation therapy [RT], or both) after resection of small bowel adenocarcinomas, and its role remains undefined. A year 2018 meta-analysis of six observational studies (totaling approximately 400 patients) concluded that there was no survival benefit for adjuvant therapy after curative resection, albeit with very wide confidence intervals (odds ratio 1.14, 95% CI 0.60-2.15) [<a href="#rid16">16</a>].</p><p>The rationale for use of systemic adjuvant therapy in small bowel adenocarcinoma is based on both the known patterns of recurrence for this disease and an extrapolation from data demonstrating a significant survival benefit in patients with node-positive colon cancer (see  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with completely resected small bowel adenocarcinoma, failure patterns are primarily systemic rather than local [<a href="#rid17">17,20,37,41</a>]. In a representative series of 146 patients undergoing potentially curative resection of a small bowel adenocarcinoma, 56 relapsed at a median time of 25 months, and the patterns of relapse were distant (n = 33), peritoneal carcinomatosis (n = 11), abdominal wall (n = 4), and local recurrence (n = 10) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One exception to this general rule is duodenal adenocarcinomas, where local failure rates as high as 41 to 50 percent are reported after surgical resection alone [<a href="#rid15">15,17,27,34,40</a>]. This provides the rational for considering chemoradiotherapy in this setting.</p><p></p><p class="headingAnchor" id="H1922676814"><span class="h4">Benefit of chemotherapy</span><span class="headingEndMark"> — </span>There are no prospective trials testing any adjuvant therapy strategy in small bowel adenocarcinoma, and the retrospective analyses that have addressed the issue have uniformly failed to suggest any overall survival benefit from any adjuvant approach [<a href="#rid6">6,17,20,24,27,33,34,40,42,43</a>]. However, treatment bias may have influenced the result. In most of these reports, the patients who were chosen for adjuvant therapy were those believed to have the highest risk of recurrence (and therefore, a worse prognosis) with surgery alone.</p><p>To control for potential treatment bias, investigators conducted a propensity score-matched analysis using data on 4746 patients with resected small bowel adenocarcinoma reported to the NCDB between 1998 and 2011 [<a href="#rid44">44</a>]. Cox regression was used to identify the covariates of overall survival, and propensity scores were developed that accounted for all factors significantly associated with either the receipt of adjuvant chemotherapy or the survival hazard from Cox modeling. In the propensity score-matched cohort of subjects receiving adjuvant chemotherapy (n = 1142) or surgery alone (n = 1155), there was a significant survival advantage for adjuvant chemotherapy versus surgery alone (median survival 63 versus 45 months, p &lt;0.001). When stratified by pathologic stage, there was a significant survival benefit for adjuvant chemotherapy for those patients with resected stage III (node-positive) disease (median 42 versus 26 months, three-year actuarial survival 55 versus 41 percent). This benefit was observed for tumor located both in the duodenum (median overall survival 34 versus 24 months, p = 0.002) and in the jejunum/ileum (median overall survival 53 versus 30 months, p = 0.003). There was only a trend toward a survival benefit for stage I and II disease, regardless of tumor location. Although suggestive of a benefit from adjuvant chemotherapy, this is not a definitive study. Propensity analysis is limited by the availability in the database of all of the variables that might impact outcomes.</p><p>Despite the lack of data from randomized trials supporting a benefit from adjuvant therapy, data from a nationwide survey, registry-based series from the NCDB, and a population-based French registry series reveal an increase in the use of adjuvant chemotherapy for regionally advanced small bowel adenocarcinoma over the last 30 years [<a href="#rid21">21,22,44,45</a>].</p><p class="headingAnchor" id="H3763312548"><span class="h4">Chemoradiotherapy for duodenal primaries</span><span class="headingEndMark"> — </span>As noted above, patients with duodenal cancer have a higher local failure rate after surgical resection alone. Separate reports have focused on the role of adjuvant chemoradiotherapy after complete resection of a duodenal adenocarcinoma:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study from the Mayo Clinic included 68 patients who had curative resection of duodenal adenocarcinoma [<a href="#rid17">17</a>]. Twenty-five recurred, 21 with distant disease. Seventeen patients received adjuvant chemoradiotherapy with concurrent FU after complete resection, but there was no significant advantage in terms of survival or cancer recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar lack of benefit for adjuvant chemoradiotherapy was noted in a multi-institutional retrospective series of 122 patients with duodenal adenocarcinoma; adjuvant chemoradiotherapy was administered to 34, and the five-year survival was no better than that of the remaining patients who did not receive it (47 versus 48 percent) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A report from Duke University compared outcomes among 16 patients treated with surgery alone with those among 16 nonrandomly assigned patients treated with either postoperative or preoperative FU-based chemoradiotherapy (50.4 Gy) in addition to surgery [<a href="#rid34">34</a>]. Adjuvant chemoradiotherapy did not significantly improve five-year overall survival (57 versus 44 percent, p = 0.42), although there was a trend favoring treatment in those who underwent a complete (R0) resection (five-year survival 83 versus 53 percent, p = 0.07), and local failure rates were lower (31 versus 44 percent).</p><p></p><p>As with prior retrospective reports, treatment bias may have influenced these results. Furthermore, the independent contribution of RT in patients receiving adjuvant chemotherapy has not been established. This issue was evaluated in a propensity score-matched analysis of 1028 patients with surgically resected duodenal adenocarcinoma who received adjuvant therapy, derived from the NCDB between 1998 and 2012 [<a href="#rid43">43</a>]. The addition of RT to adjuvant chemotherapy did not significantly improve survival, even in high-risk patients (ie, node-positive, T4 primary tumors, inadequate lymph node staging, poorly differentiated histology, or margin-positive resections).</p><p class="headingAnchor" id="H7"><span class="h3">Indications for neoadjuvant therapy</span><span class="headingEndMark"> — </span>Although neoadjuvant chemotherapy and/or chemoradiotherapy has only been studied in a very small number of patients, this approach is promising [<a href="#rid34">34,46-48</a>]. In the largest report of 32 patients with localized duodenal adenocarcinoma, 2 of 11 patients treated with preoperative RT and concurrent FU-based chemotherapy had a pathologic complete response [<a href="#rid34">34</a>]. All were subsequently resected, and none of the 11 had involved lymph nodes at the time of resection.</p><p>There are no widely accepted criteria for selecting patients for a neoadjuvant approach. Guidelines from the NCCN suggest initial oxaliplatin-containing chemotherapy (FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 3</a>), or CAPOX  (<a class="graphic graphic_table graphicRef96117" href="/d/graphic/96117.html" rel="external">table 2</a>) or FOLFOXIRI  (<a class="graphic graphic_table graphicRef70559" href="/d/graphic/70559.html" rel="external">table 4</a>)), possibly followed by chemoradiotherapy (for a duodenal primary) in patients with locally unresectable disease and for those who are medically inoperable, followed by reevaluation for conversion to resectable disease [<a href="#rid5">5</a>]. We consider the use of neoadjuvant chemotherapy on a case-by-case basis, mainly in patients with bulky or locally advanced categorically unresectable disease.</p><p class="headingAnchor" id="H8"><span class="h2">Metastatic disease</span></p><p class="headingAnchor" id="H9"><span class="h3">Systemic therapy</span></p><p class="headingAnchor" id="H446901365"><span class="h4">Conventional cytotoxic therapy</span><span class="headingEndMark"> — </span>For patients who are able to tolerate it, we suggest systemic chemotherapy rather than supportive care alone. We use an oxaliplatin-based chemotherapy regimen as a first-line regimen.</p><p>In the absence of randomized trials comparing different chemotherapy regimens, the majority of phase II and retrospective data support a fluoropyrimidine plus a platinum-type drug for first-line chemotherapy in patients with advanced small bowel adenocarcinoma. We prefer the CAPOX  (<a class="graphic graphic_table graphicRef61781" href="/d/graphic/61781.html" rel="external">table 5</a>) or mFOLFOX6  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 3</a>) regimens, or if a patient is not an appropriate candidate for intensive therapy, a fluoropyrimidine alone (<a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or leucovorin-modulated FU). The NCCN guidelines recommend <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> and leucovorin-modulated FU (FOLFOXIRI) as an option and this is a reasonable alternative, though no data in small bowel adenocarcinoma exist, and this recommendation is based upon extrapolation from the treatment of colorectal cancer. The use of treatments targeting vascular endothelial growth factor (VEGF, eg, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>) is controversial as there are no data from randomized trials demonstrating the benefit of adding bevacizumab to a backbone cytotoxic regimen in advanced small bowel adenocarcinoma.</p><p>In general, systemic chemotherapy for patients with advanced small bowel adenocarcinoma has been based on treatment principles established for metastatic colorectal cancer. (See  <a class="medical medical_review" href="/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles"</a> and  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a> and  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy"</a>.)</p><p>Although randomized trials have not been undertaken, a number of retrospective series suggest that patients with metastatic or locally advanced unresectable small bowel adenocarcinoma who get chemotherapy live longer than do those who do not receive chemotherapy  (<a class="graphic graphic_table graphicRef53789" href="/d/graphic/53789.html" rel="external">table 6</a>) [<a href="#rid20">20,33,49-51</a>]. However, since it is likely that chemotherapy was offered to healthier patients with more indolent disease biology, selection bias likely accounts for at least some of these findings.</p><p>The majority of published reports evaluating chemotherapy for small bowel adenocarcinoma are retrospective in nature. Relatively few prospective phase II studies have been reported:</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-institution study, the CAPOX regimen (<a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> 750 mg/m<sup>2</sup> twice daily on days 1 through 14, and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> 130 mg/m<sup>2</sup> on day 1, every 21 days) was administered to 31 patients with advanced, unresectable or metastatic small bowel or ampullary adenocarcinoma [<a href="#rid52">52</a>]. Among the 25 patients with metastatic disease, the response rate was 52 percent (with three complete responses) and median overall survival was 15.5 months. The response rate in the subgroup of 18 patients with small bowel adenocarcinoma was 61 versus 33 percent with ampullary adenocarcinoma.</p><p></p><p class="bulletIndent1">The optimum dose of <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> for use in the CAPOX regimen is debated. However, based on the above trial, we suggest use of 750 mg/m<sup>2</sup> twice daily on days 1 through 14 of each 21-day cycle  (<a class="graphic graphic_table graphicRef96117" href="/d/graphic/96117.html" rel="external">table 2</a>), rather than the 850 mg/m<sup>2</sup> dose as is commonly used for treatment of colorectal cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encouraging results were also seen with CAPOX or the modified FOLFOX6 regimen  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 3</a>) in a multicenter phase II trial of 24 patients with locally unresectable or metastatic small bowel adenocarcinoma [<a href="#rid53">53</a>]. The objective response and disease control rates were 32.3 and 61.7 percent, respectively, and median duration of progression-free and overall survival were 6.3 and 14.2 months, respectively.</p><p></p><p class="bulletIndent1">A second multicenter phase II trial of 33 patients using a modified FOLFOX regimen (FU 2600 mg/m<sup>2</sup> continuous infusion over 46 hours starting day 1, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> 85 mg/m<sup>2</sup> on day 1, <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> 400 mg/m<sup>2</sup> day 1, every 14 days) demonstrated an objective response rate of 49 percent, median TTP of 7.8 months, and median OS of 15.2 months [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The addition of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> to a fluoropyrimidine and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> combination demonstrated similar activity [<a href="#rid55">55</a>]. Among 28 patients with advanced small bowel adenocarcinoma receiving UGT1A1 genotype-selected dosing of irinotecan, oxaliplatin, and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, the objective response rate was 57 percent and median progression-free survival (PFS) and overall survival were 8.7 and 12.7 months. UGT1A1 genotype dosing of these chemotherapy agents is not a standard widely accepted practice. (See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'UGT1A1 polymorphisms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A potential role for taxanes was suggested in a phase II study of nanoparticle albumin-bound <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (<a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>); 2 of the 10 enrolled patients with small bowel adenocarcinoma had an objective response [<a href="#rid56">56</a>].</p><p></p><p>The efficacy of other regimens for the treatment of small bowel adenocarcinoma has been examined in retrospective case series [<a href="#rid49">49-52,57-65</a>]. The following represents the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>One series included 80 patients with metastatic small bowel adenocarcinoma treated at MD Anderson between 1978 and 2005 with a variety of chemotherapy regimens [<a href="#rid58">58</a>]. Twenty-nine patients received FU with a platinum (19 <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, four <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, six <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>), 41 received FU-based therapy without a platinum (FU alone in 32, FAM or FU and <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> in six, and other FU combinations in three), and 10 received non-platinum and non-FU-based therapy.</p><p></p><p class="bulletIndent1">Compared with other regimens, FU combined with a platinum drug was associated with significantly higher objective response rates (46 percent versus 16 percent with all others) and median PFS (8.7 versus 3.9 months), but median overall survival was comparable (14.8 versus 12 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another report included 93 patients with advanced small bowel adenocarcinoma (86 percent metastatic) who were treated with leucovorin-modulated FU, FOLFOX (<a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> and short-term infusional FU), FOLFIRI (<a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus leucovorin and short-term infusional FU), or FU plus leucovorin and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid65">65</a>]. Although this was not a randomized trial, response rates were highest with FOLFOX (13 of 38 partial responses, 34 percent), and median overall survival was also highest in the patients treated with FOLFOX (17.8 months).</p><p></p><p class="bulletIndent1">An apparent survival advantage for fluoropyrimidine/<a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> combination therapy over other regimens in the setting of advanced small bowel adenocarcinoma has also been shown by others [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">Irinotecan</a> and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> are also active agents [<a href="#rid49">49,50,59,60,63,64,67</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the series of 44 patients undergoing palliative therapy for advanced disease described above, 5 of the 12 patients receiving irinotecan-based therapy (six FOLFIRI  (<a class="graphic graphic_table graphicRef76300" href="/d/graphic/76300.html" rel="external">table 7</a>), two <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, and four single agent irinotecan) had a partial response (42 percent) [<a href="#rid49">49</a>]. Less impressive results have been reported with second-line FOLFIRI after failure of initial platinum-based chemotherapy (response rate 20 percent, median PFS 3.2 months) [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The activity of first-line <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> was addressed in the series of 44 patients undergoing palliative therapy for advanced disease described above [<a href="#rid49">49</a>]. Seven of 17 patients (41 percent) receiving a gemcitabine-based regimen (nine single-agent gemcitabine, four gemcitabine plus FU, four gemcitabine plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>) had an objective response.</p><p></p><p class="headingAnchor" id="H891610274"><span class="h4">Molecular profiling and targeted therapies</span><span class="headingEndMark"> — </span>We recommend multigene panel-based somatic genomic testing for all metastatic small bowel adenocarcinomas, if the patient would be a candidate for targeted therapy.</p><p>Increasingly, biomarker expression is driving therapeutic decision making in patients with advanced refractory cancer. Small bowel adenocarcinomas have a different genomic profile compared with colorectal and gastric adenocarcinomas, including variations in the frequency and types of alterations of <em>KRAS</em>, <em>APC</em>, <em>BRAF</em>, <em>ERBB2</em>/<em>HER2</em>, and other genes, some of which may be potentially actionable targets for therapy [<a href="#rid68">68-70</a>]. Multigene panel-based somatic (tumoral) genomic testing has the potential to identify targetable alterations and patients for whom targeted therapies might be of benefit. In some cases, germline testing may also reveal potential treatment targets (eg, deficient mismatch repair as seen in Lynch syndrome). (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Germline mutation'</a>.)</p><p>ASCO has issued a provisional clinical opinion that supports germline and somatic genomic testing in metastatic or advanced cancer when there are genomic biomarker-linked therapies approved by regulatory agencies for their cancer [<a href="#rid71">71</a>]. Given the tissue-agnostic approvals for any advanced refractory cancer with a high tumor mutational burden or DNA mismatch repair deficiency (checkpoint inhibitor immunotherapy), or neurotrophic tyrosine receptor kinase (<em>NTRK</em>) fusions (TRK inhibitors), or <em>RET</em> (rearranged in transfection) fusions (<a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">selpercatinib</a>), this provides a rationale for testing for all solid tumors, if the individual would be a candidate for these treatments. Testing should also be considered to determine candidacy for targeted therapies approved for other diseases in patients without approved genomic biomarker-linked therapy; however off-label/off-study use of such therapies is not recommended when a clinical trial is available, or without evidence of meaningful efficacy in clinical trials. (See  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Cancer screening and management'</a> and  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a> and  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a>.)</p><p>However, few data are available exploring the benefit of specific biologic or targeted therapies in advanced small bowel adenocarcinoma :</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a> is a monoclonal antibody targeting VEGF. Bevacizumab (7.5 mg/kg every 21 days) was combined with CAPOX (<a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> 750 mg/m<sup>2</sup> twice daily on days 1 through 14 and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> 130 mg/m<sup>2</sup> on day 1 every 21 days) in a single-institution phase II study of 30 patients with advanced, unresectable or metastatic small bowel or ampullary adenocarcinoma [<a href="#rid72">72</a>]. Treatment was reasonably well tolerated, and the response rate was 48 percent, median PFS was 8.7 months, and median overall survival was 12.9 months. Whether these results are better than could be achieved with CAPOX will require a randomized trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited data are available for the role of anti-epidermal growth factor receptor (EGFR) therapy. Among patients with advanced colorectal cancer, <em>RAS</em> mutations are associated with resistance to agents that target EGFR (see  <a class="medical medical_review" href="/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'RAS'</a>). In addition, given more recent colorectal data suggesting that anti-EGFR therapy effectiveness relates to colon sidedness, the role of anti-EGFR therapy in small bowel adenocarcinoma, given its midgut derivation (right sidedness), is uncertain:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible benefit for <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, a monoclonal antibody targeting EGFR, was suggested in a report of four patients with advanced small bowel adenocarcinoma who received the drug in conjunction with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>; two had previously failed an irinotecan-based combination regimen [<a href="#rid73">73</a>]. There were three objective responses, one of which was complete. Three of the four patients had wild-type <em>K-ras</em> tumors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An additional case report describes a minor response to single agent <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> in a patient with metastatic duodenal adenocarcinoma whose <em>K-ras</em> status was wild-type [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On the other hand, benefit for single-agent <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a> (a different anti-EGFR antibody) could not be shown in a small prospective study of eight patients with <em>RAS</em> wild-type small bowel adenocarcinoma [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>ERBB2</em> alterations occur in approximately 10 to 20 percent of small bowel adenocarcinoma, although alterations tend to be activating mutations, in contrast to in colorectal cancer, where amplifications are more common [<a href="#rid68">68</a>]. One study that examined preclinical models of <em>ERBB2</em>-mutated small bowel adenocarcinoma patient-derived xenografts and cell lines demonstrated activity from small molecular inhibitors of ERBB2 [<a href="#rid69">69</a>]. However, no clinical data are currently available assessing the efficacy of ERBB2-targeted therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>RET</em> fusions are rare in small bowel cancer [<a href="#rid76">76</a>]. However, in September 2022, the US Food and Drug Administration granted a tissue-agnostic, accelerated approval to the RET tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="128157" href="/d/drug information/128157.html" rel="external">selpercatinib</a>, for adult patients with locally advanced or metastatic solid tumors, including small bowel cancers, with a <em>RET</em> gene fusion and disease progression on or following prior systemic treatment who have no satisfactory alternative treatment options. The phase I/II basket trial (LIBRETTO-001) of selpercatinib for <em>RET</em> fusion positive solid tumors included only two patients with small bowel cancer, but one had a complete clinical response [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H4101885089"><span class="h4">Indications for immunotherapy</span><span class="headingEndMark"> — </span>For patients whose tumors are dMMR or that have high levels of TMB (≥10 mutations/megabase), another option for chemotherapy-refractory disease is treatment with an immune checkpoint inhibitor that targets the programmed death receptor 1 (PD-1; ie, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>). We do not suggest a trial of pembrolizumab for other groups of patients [<a href="#rid78">78</a>], unless in the context of a clinical trial.</p><p>Immunotherapeutic approaches to cancer therapy are based on the premise that the immune system plays a key role in surveillance and eradication of malignancy and that tumors evolve ways to elude the immune system. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deficient mismatch repair</strong> – Some cancers with deficient mismatch repair (dMMR) are particularly sensitive to immune-based therapies. Objective, in some instances complete, and durable responses to immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1; eg, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>) have been reported in a variety of patients with dMMR cancers, including small bowel adenocarcinomas. The characteristic genetic signature of tumors with dMMR is a high number of DNA replication errors and high levels of DNA MSI. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p></p><p class="bulletIndent1">Mutations in one of several DNA MMR genes are found in Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) and in some small bowel adenocarcinomas. (See  <a class="medical medical_review" href="/d/html/2484.html" rel="external">"Pathology and prognostic determinants of colorectal cancer", section on 'Mismatch repair deficiency'</a> and  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1">The fraction of small intestine cancers that are dMMR has been addressed in the following reports:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, approximately 8 percent of small intestinal malignancies were dMMR or MSI-H [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variable levels of dMMR have been reported for small bowel tumors when the analysis has been limited to individuals with advanced/metastatic disease (1 percent in one study [<a href="#rid79">79</a>], 8 percent in a second [<a href="#rid68">68</a>], and approximately 16 percent in a third study [<a href="#rid80">80</a>]).</p><p></p><p class="bulletIndent1">In the United States, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is approved for treatment of a variety of advanced solid tumors, including small bowel adenocarcinomas, that are MSI-H or dMMR, that have progressed following prior treatment, and for which there are no satisfactory alternative treatment options, the first such approval of a tissue-agnostic anticancer treatment. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p></p><p class="bulletIndent1">Efficacy in dMMR small intestine cancers was shown in the phase II KEYNOTE-158 study, which enrolled 19 patients with small bowel cancer [<a href="#rid81">81</a>]. There were eight objective responses (42 percent), three of which were complete, and the duration of response ranged from 4.3 to 13.3+ months.</p><p></p><p class="bulletIndent1">An important point is that MSI-H or dMMR may indicate the presence of Lynch syndrome, an inherited condition that predisposes to several cancers, including small bowel adenocarcinoma. All patients with an MSI-H/dMMR small bowel adenocarcinoma should undergo germline genetic assessment for Lynch syndrome, regardless of age or family history [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'</a>.)</p><p></p><p class="bulletIndent1">The approach to testing for dMMR is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Assessing mismatch repair'</a> and  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Approach to testing dMMR as a predictive marker'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High tumor mutational burden</strong> – Tumors with a high tumor mutational burden (TMB) also appear to be sensitive to immune checkpoint inhibitors. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumor mutational burden'</a>.)</p><p></p><p class="bulletIndent1">Approximately 8 to 12 percent of small bowel adenocarcinomas have high levels of TMB, defined as ≥10 mutations per megabase (muts/mB) [<a href="#rid68">68,83</a>].</p><p></p><p class="bulletIndent1">In June 2020, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was approved for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors, including small bowel adenocarcinomas, that are tissue TMB-high (≥10 mut/mB) and who have progressed following prior therapy and who have no satisfactory alternative treatment options. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Treatment of the primary tumor</span><span class="headingEndMark"> — </span>Palliative surgical resection of the primary tumor may be needed in patients with locally advanced unresectable or metastatic small bowel adenocarcinoma to manage bowel obstruction or bleeding. For tumors located in the duodenum, RT may provide local disease control or control of bleeding, and for nonsurgical palliation of duodenal obstruction, an endoscopic duodenal stent can be placed. (See  <a class="medical medical_review" href="/d/html/2676.html" rel="external">"Enteral stents for the palliation of malignant gastroduodenal obstruction"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Potentially resectable metastases</span><span class="headingEndMark"> — </span>Potentially resectable metastases are rare with small bowel adenocarcinoma. Limited information is available regarding metastasectomy in this setting. Two series report no long-term survivors among a small number of patients undergoing surgery for hepatic metastases from small bowel adenocarcinoma [<a href="#rid84">84,85</a>]. On the other hand, potential benefit for hepatic resection is suggested by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Adam and colleagues reported encouraging data in a large series of patients with hepatic metastases from a noncolorectal cancer primary that included 28 patients with jejunal or ileal adenocarcinoma and 12 patients with a duodenal adenocarcinoma [<a href="#rid86">86</a>]. Five-year survival postresection was 49 percent for the jejunal/ileal group and 21 percent for the duodenal group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study from Johns Hopkins evaluating the benefit of resection of synchronous hepatic metastases for periampullary tumors, two patients had duodenal adenocarcinoma, one of whom represented the longest survivor at 39.5 months [<a href="#rid87">87</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Isolated peritoneal carcinomatosis</span><span class="headingEndMark"> — </span>Long-term survival has been reported after aggressive cytoreduction surgery and intraperitoneal hyperthermic chemotherapy in highly selected patients with isolated peritoneal carcinomatosis from a small bowel adenocarcinoma [<a href="#rid88">88-91</a>]. One retrospective study of four tertiary referral centers in the Netherlands included 16 patients who underwent cytoreductive surgery and intraperitoneal hyperthermic chemotherapy [<a href="#rid89">89</a>]. Median disease-free survival was 9.5 months, and eight patients had a disease recurrence, although median follow-up time was short at only 16.5 months. Highly selected patients being considered for this approach should be referred to a center with expertise in the management of peritoneal surface malignancies. (See  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix"</a> and  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging"</a>.)</p><p class="headingAnchor" id="H611954160"><span class="h2">Post-treatment surveillance</span><span class="headingEndMark"> — </span>There are no guidelines for post-treatment surveillance for small bowel adenocarcinoma from the American Society of Clinical Oncology (ASCO) or the European Society of Medical Oncology (ESMO). Guidelines from the NCCN generally follow a similar approach as for resected colon cancer, but with some exceptions [<a href="#rid5">5</a>] (see  <a class="medical medical_review" href="/d/html/2493.html" rel="external">"Post-treatment surveillance after colorectal cancer treatment"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination every 3 to 6 months for two years, then every 6 months for a total of five years</p><p class="bulletIndent1"><span class="glyph">●</span>Chest/abdomen/pelvic CT every 6 to 12 months for two years, then annually for a total of five years</p><p class="bulletIndent1"><span class="glyph">●</span>Assay of tumor markers CEA and/or CA 19-9-every 3 to 6 months for two years, then every 6 months for a total of five years</p><p class="bulletIndent1"><span class="glyph">●</span>Routine capsule endoscopy is not indicated</p><p></p><p>Most of the authors and editors associated with this topic review follow these guidelines. Patients can also be followed according to published post-treatment surveillance guidelines for colon cancer, which are available from several expert groups and are compared and contrasted in the table  (<a class="graphic graphic_table graphicRef91618" href="/d/graphic/91618.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/d/html/2493.html" rel="external">"Post-treatment surveillance after colorectal cancer treatment"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">NEUROENDOCRINE TUMORS</span></p><p class="headingAnchor" id="H15"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Neuroendocrine tumors (NETs) arising in the jejunum and ileum are typically well differentiated and generally act as biologically indolent tumors. Five-year survival rates for small bowel NETs arising in the jejunum or ileum are between 52 and 100 percent depending on the stage of disease  (<a class="graphic graphic_table graphicRef111096" href="/d/graphic/111096.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef111095" href="/d/graphic/111095.html" rel="external">table 10</a>) [<a href="#rid21">21,36,92-94</a>]. Rates may be lower for a clinical presentation of an ileal NET with a large mesenteric mass &gt;2 cm (five-year survival rates 65 versus 93 percent in one series for those with and without a large mesenteric mass [<a href="#rid95">95</a>]). Duodenal primaries may have a more heterogeneous behavior regardless of lymphatic spread [<a href="#rid96">96</a>].</p><p>However, even among patients with distant metastasis, 10-year survival rates of 40 to 60 percent are reported. Ten-year disease-specific survival rates stratified according to the 2010 American Joint Committee on Cancer (AJCC) stage groupings from a series of 6792 patients with small intestine NETs derived from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) registry were as follows [<a href="#rid97">97</a>] (see  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Small intestine'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Stage I – 95 percent (95% CI 93-97 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IIA – 95 percent (95% CI 90-96 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IIB – 77 percent (95% CI 71-83 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IIIA – 68 percent (95% CI 58-77 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IIIB – 77 percent (95% CI 74-80 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IV – 42 percent (95% CI 38-46 percent)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Treatment of locoregional disease</span><span class="headingEndMark"> — </span>NETs of the small bowel have the potential to metastasize, even when &lt;2 cm in size  (<a class="graphic graphic_table graphicRef82306" href="/d/graphic/82306.html" rel="external">table 11</a>). In a survey of published literature in which tumor size was reported and a distinction made between metastases to the regional nodes and distant sites, small bowel NETs less than 1 cm in size had nodal and distant metastases present at discovery in 12 and 5 percent, respectively [<a href="#rid92">92</a>]. For tumors between 1.1 and 1.9 cm, nodal or distant metastases were present in 70 and 19 percent of patients, respectively, while NETs exceeding 2 cm were associated with nodal and distant metastases in 85 and 47 percent of cases, respectively. Similar results have been published by others [<a href="#rid98">98</a>]. Even higher rates of nodal metastases for lesions ≤1 cm are reported for duodenal NETs [<a href="#rid99">99</a>].</p><p>Because of this, the surgical management of small bowel NETs differs from that of appendiceal NETs (for which a local excision [appendectomy] is considered adequate for a tumor smaller than 1.5 to 2.0 cm in the absence of invasion of the mesoappendix, blood vessels, or regional nodes). (See  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix", section on 'Treatment of localized disease'</a>.)</p><p>Most surgeons recommend a wide en bloc resection that includes the adjacent mesentery and lymph nodes for a small bowel NET of any size [<a href="#rid100">100-106</a>]. This operation may cure a greater proportion of patients, and it provides better local disease control. Such a resection may be difficult at times if fibrosis and foreshortening of the mesentery are present. Outcomes are better among patients who undergo complete (R0) resection  (<a class="graphic graphic_table graphicRef62793" href="/d/graphic/62793.html" rel="external">table 12</a>) [<a href="#rid107">107</a>]. Retrieval of at least eight lymph nodes appears to be optimal to achieve accurate staging [<a href="#rid108">108</a>].</p><p>Since approximately 40 percent of patients with midgut NETs have a second gastrointestinal tract malignancy, the entire bowel and colon should be evaluated prior to any surgical intervention. Intraoperative assessment, including "running the bowel," should also be performed to exclude multiple sites of NETs of the small bowel. (See  <a class="medical medical_review" href="/d/html/2517.html" rel="external">"Epidemiology, clinical features, and types of small bowel neoplasms"</a> and  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Small intestine'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Treatment of advanced disease</span></p><p class="headingAnchor" id="H18"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>The role of surgery for metastatic NETs arising in the small bowel is not clearly defined. When metastatic disease is present (usually to the liver), it is necessary to establish whether the patient has symptoms of carcinoid syndrome and whether curative resection is possible. In an asymptomatic patient, if there are no contraindications to surgery, and the metastases appear resectable, then an attempt at complete extirpation is usually undertaken. Resection of hepatic metastases prolongs disease-free survival, and it may possibly increase overall survival as well. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a>.)</p><p>Carcinoid syndrome is the term applied to a constellation of symptoms mediated by various humoral factors elaborated by NETs  (<a class="graphic graphic_table graphicRef79329" href="/d/graphic/79329.html" rel="external">table 13</a>). Two of the most common manifestations are episodic flushing and diarrhea  (<a class="graphic graphic_table graphicRef63079" href="/d/graphic/63079.html" rel="external">table 14</a>). Ninety percent of patients with NETs and the carcinoid syndrome have metastatic disease, typically to the liver. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p>Surgery plays a limited role in the treatment of most patients with the carcinoid syndrome because almost all have extensive unresectable metastatic disease. Symptomatic relief may be obtained by debulking surgery; however, the duration of effective relief from these palliative procedures can be short, usually less than 12 months. On the other hand, treatment with somatostatin analogs usually provides longer-term adequate symptomatic relief. (See <a class="local">'Systemic therapy'</a> below.)</p><p>The indications for resection of the primary site in patients with metastatic disease are not well established, and there is little consensus on this issue. In general, at the time of surgical resection of metastatic disease, it is recommended to resect a primary intestinal NET in order to prevent the development of complications such as bowel obstruction or intestinal ischemia; whether or not removal of the primary tumor improves survival is controversial. However, prophylactic surgery is usually not undertaken unless surgery is being performed for another reason, or if serial computed tomography (CT) scans demonstrate the development of fibrosing mesenteritis. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Management of the primary tumor in patients with metastatic disease'</a>.)</p><p>Surgical procedures in patients with carcinoid syndrome are potentially hazardous due to the precipitation of carcinoid crisis during induction of anesthesia or surgical manipulation of tumors. Prevention and management of carcinoid crisis is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome", section on 'Carcinoid crisis: prevention and management'</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Nonsurgical liver-directed therapy</span><span class="headingEndMark"> — </span>Due to the hypervascular nature of NET metastases, hepatic arterial embolization is frequently applied as a palliative technique in patients with hepatic metastases who are not candidates for surgical resection. The response rates associated with bland embolization or chemoembolization, as measured either by decrease in hormonal secretion or by radiographic regression, are generally greater than 50 percent. However, the duration of response can be brief, ranging from 4 to 24 months in uncontrolled series. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic arterial embolization'</a>.)</p><p>Another form of nonsurgical liver-directed therapy is radioembolization using yttrium-labeled microspheres. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic arterial embolization'</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Systemic therapy</span><span class="headingEndMark"> — </span>The systemic management of well-differentiated neuroendocrine tumors is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.)</p><p class="headingAnchor" id="H611954223"><span class="h2">Post-treatment surveillance</span><span class="headingEndMark"> — </span>Clinical practice is variable with respect to post-treatment surveillance, particularly as to the use of serum tumor markers. Recommendations for post-treatment surveillance, including those from expert groups such as the National Comprehensive Cancer Network (NCCN) [<a href="#rid109">109</a>] and European Neuroendocrine Tumor Society (ENETS), are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Post-treatment follow-up'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SARCOMA</span><span class="headingEndMark"> — </span>Malignant mesenchymal tumors of the gastrointestinal tract fall into two categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal stromal tumors (GIST), which comprise &gt;85 percent of all sarcomas arising within the gastrointestinal tract</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The various other soft tissue sarcomas that arise at other sites, including leiomyosarcoma, fibrosarcoma, liposarcoma, Kaposi sarcoma, and angiosarcoma, collectively referred to as non-GIST gastrointestinal sarcomas</p><p></p><p>GISTs and leiomyosarcomas can have a similar morphologic appearance, but their distinction is important because treatment, particularly in the setting of advanced disease, differs markedly. Approximately 85 percent of GISTs have activating mutations in the <em>KIT</em> protooncogene, which leads to constitutive expression of KIT, a receptor tyrosine kinase. A subset of GISTs lacking <em>KIT</em> mutations have activating mutations in a related receptor tyrosine kinase, the platelet-derived growth factor receptor alpha (<em>PDGFRA</em>) gene. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Pathogenesis'</a>.)</p><p><a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> mesylate is a selective inhibitor of <em>KIT</em> and <em>PDGFR</em>A, and has become the first-line therapy for advanced GIST. For localized cases that are borderline resectable or for which surgical resection might result in significant functional deficit (eg, loss of the esophagogastric junction), initial (neoadjuvant) imatinib may be considered. Testing the tumor for mutation is recommended prior to starting preoperative imatinib to ensure that the tumor has a genotype that will respond to treatment. For localized GIST, which are potentially resectable with negative margins and minimal morbidity, surgical resection is the preferred initial therapy. (See  <a class="medical medical_review" href="/d/html/2516.html" rel="external">"Diagnosis and staging of small bowel neoplasms", section on 'Histology and differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"</a> and  <a class="medical medical_review" href="/d/html/7727.html" rel="external">"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract"</a>.)</p><p class="headingAnchor" id="H3652615591"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgical treatment for localized, potentially resectable GISTs and non-GIST primary sarcomas of the small bowel is similar. In general, en bloc segmental resection with tumor-free margins is the primary treatment modality for both and preferred over peritumoral resection. Every effort should be made not to violate the pseudocapsule of the tumor to avoid spillage of the tumor. If laparoscopic surgery is performed, the tumor should be extracted in an Endocatch bag to avoid tumor spillage or seeding of port sites. Unlike adenocarcinomas and neuroendocrine tumors, sarcomas infrequently metastasize to regional mesenteric lymph nodes, and routine mesenteric lymphadenectomy is neither necessary nor beneficial. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors"</a> and  <a class="medical medical_review" href="/d/html/7727.html" rel="external">"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Small intestine'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Adjuvant and neoadjuvant treatment</span><span class="headingEndMark"> — </span>Before 2001, surgery was the only available treatment for GISTs. However, in approximately one-half of patients, complete resection was not possible, and median survival ranged from 10 to 23 months. Dramatic improvements in tumor control occurred with the recognition that mutational activation of KIT or a second receptor tyrosine kinase, PDGFRA, stimulated the growth of these cancer cells, and that growth could be inhibited with orally active small molecule tyrosine kinase inhibitors (TKIs) such as <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. Among patients with overt metastatic disease, 80 percent experience an objective response or disease stability, median progression-free survival (PFS) is 20 to 26 months, and median overall survival is 51 to 57 months. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a>.)</p><p>The success of these agents in the setting of advanced disease prompted interest in their use as adjuvant therapy after complete resection of a GIST or as preoperative (induction or neoadjuvant) therapy in patients with locally advanced disease:</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with activating <em>KIT</em> mutations, adjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> is recommended for at least three years following resection of a high-risk GIST. This recommendation is based on the results of the Scandinavian Sarcoma Group (SSG) XVIII trial, which compared 36 versus 12 months of adjuvant imatinib (400 mg daily) in 400 patients with a high-risk resected GIST (defined according to the modified consensus criteria [<a href="#rid110">110</a>] as having at least one of the following: tumor size &gt;10 cm, mitotic count &gt;10 per 50 high-power fields [HPF], tumor size &gt;5 cm with mitotic rate &gt;5 per 50 HPF, or tumor rupture) [<a href="#rid111">111</a>]. Prolonged treatment was associated with a significant improvement in relapse-free survival as well as overall survival. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Benefit of imatinib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with locally advanced disease, preoperative <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> has been recommended as a treatment strategy to facilitate resection and decrease surgical morbidity of the resection by reducing the need for multivisceral resection, and diminish the risk of preoperative tumor rupture and intraoperative spillage of live tumor cells. However, a disadvantage of preoperative imatinib is the inability to fully assess tumoral mitotic rate, a major prognostic factor. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'</a>.)</p><p></p><p>The role of adjuvant or neoadjuvant chemotherapy for small bowel sarcomas other than GIST tumors is undefined.</p><p class="headingAnchor" id="H23"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Small bowel GISTs have been long considered to have an inferior prognosis as compared with those arising in the stomach. However, more recent data have challenged this notion. A study utilizing the Surveillance, Epidemiology, and End Results (SEER) database from 2002 to 2012 reported on 3759 patients with gastric GIST and 1848 patients with small intestine GIST [<a href="#rid112">112</a>]. Five-year survival was 83.3 percent for small intestine GIST, compared with 82.2 percent for gastric GIST. On multivariable analysis, male sex, nodal disease, and radiation therapy were the only negative prognostic factors for small intestine GIST patients. Black American patients survived only approximately half as long as White American patients.</p><p>The prognosis of small intestine GISTs depends on the tumor site, adequacy of resection, tumor size, and mitotic activity  (<a class="graphic graphic_table graphicRef139776 graphicRef60930" href="/d/graphic/139776.html" rel="external">table 15A-B</a>). The Memorial Sloan Kettering Cancer Center offers a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mskcc.org%2Fnomograms%2Fgastrointestinal%2Fstromal_tumor&amp;token=p3hikKg%2BBYqUIHzXEIJ8vQt1d4W45I4lb4lUVTqB6Xv7c7SJ8hZ34%2BYOs%2BeEeTtmQla2C9lKVpE1%2Fqow10%2BiUa8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=2509" target="_blank">GIST nomogram</a> designed to predict the likelihood of tumor recurrence two and five years following complete resection without the addition of TKIs. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Estimation of recurrence risk'</a> and  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Prognostic and risk stratification models'</a>.)</p><p class="headingAnchor" id="H611954261"><span class="h2">Post-treatment surveillance</span><span class="headingEndMark"> — </span>There are no evidence-based guidelines on what constitutes appropriate follow-up after treatment of a GIST, and there is no consensus on this issue. Recommendations, including those from expert groups such as the National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO), are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7727.html" rel="external">"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'GIST'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">LYMPHOMA</span><span class="headingEndMark"> — </span>Primary gastrointestinal (GI) lymphomas can be operationally defined as lymphomas in which the main bulk of disease is confined to the GI tract. The most common subtypes of primary small intestinal non-Hodgkin lymphoma are diffuse large B cell lymphoma, enteropathy-associated T cell intestinal lymphoma, extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT), mantle cell lymphoma, and Burkitt and Burkitt-like lymphoma. Hodgkin lymphoma is extremely rare. (See  <a class="medical medical_review" href="/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a>.)</p><p>The pathology, clinical features, and prognosis of intestinal lymphomas may differ from lymphomas of lymph node origin. As an example, indolent lymphomas of lymph node origin are almost always disseminated at diagnosis, have frequent bone marrow involvement, generally respond to therapy, but continuously recur. Median survival can exceed 10 years, although cure is unusual. On the other hand, MALT and MALT-type lymphomas, also considered indolent forms of lymphoma, are often localized at diagnosis, and long-term disease-free survival and cure are common. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>Nevertheless, the treatment approach to a small bowel lymphoma generally parallels the standard treatment approach for that histologic subtype of lymphoma arising in nodal regions. The unique situation that can arise in patients with lymphoma of the small intestine is in patients who undergo surgical resection of localized stage IE or IIE disease  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 16</a>) for diagnostic purposes or because of the presence of obstruction or perforation. In such cases, outcomes following surgery alone are poor with five-year survival rates of approximately 45 percent for stage IE disease and 19 percent for stage IIE disease. Systemic chemotherapy is indicated in this situation, even if resection is complete.</p><p>The management and chemotherapy approach for lymphomas involving the GI tract is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">METASTATIC LESIONS</span><span class="headingEndMark"> — </span>Involvement of the small bowel is not uncommon in the context of widespread peritoneal carcinomatosis. However, hematogenous spread of metastatic disease to the small intestine is rare. In studies in which direct extension from an adjacent primary tumor was excluded, the most common cancers to involve the small bowel were melanoma, lung, breast, cervix, sarcoma, and colon [<a href="#rid113">113-115</a>].</p><p>Treatment of these lesions is palliative; limited resection or intestinal bypass may be needed to relieve symptoms. For nonsurgical palliation of duodenal obstruction, an endoscopic duodenal stent can be placed. (See  <a class="medical medical_review" href="/d/html/2676.html" rel="external">"Enteral stents for the palliation of malignant gastroduodenal obstruction"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">TREATMENT OF BENIGN NEOPLASMS</span><span class="headingEndMark"> — </span>Treatment recommendations for benign neoplasms arising in the small bowel vary from endoscopic removal to radical resection (eg, pancreaticoduodenectomy or duodenectomy), depending on the type of neoplasm, size, location, number, and malignant potential.</p><p class="headingAnchor" id="H27"><span class="h2">Adenoma</span><span class="headingEndMark"> — </span>In general, simple tubular adenomas and Brunner gland tumors have a low malignant potential; they can be cured by endoscopic polypectomy, simple local resection, or submucosal resection [<a href="#rid116">116,117</a>]. Villous adenomas have a malignant potential similar to their colonic counterparts; up to 30 percent may harbor malignancy, depending on size. Nevertheless, endoscopic polypectomy or simple resection is sufficient as long as no invasive carcinoma is found in the specimen [<a href="#rid116">116-118</a>].</p><p>Many clinicians advocate radical pancreaticoduodenectomy for periampullary duodenal villous adenomas because of the difficulty in making a preoperative diagnosis and in obtaining an adequate resection without sacrificing the ampulla. However, one study found that local submucosal excision produced acceptable long-term results if the tumor did not have areas of invasive cancer; 17 percent recurred after five years of follow-up [<a href="#rid119">119</a>]. Periampullary adenomas containing areas of malignant growth (in situ or invasive) still require radical surgery. (See  <a class="medical medical_review" href="/d/html/649.html" rel="external">"Ampullary adenomas: Management"</a>.)</p><p>For patients who have duodenal adenomas in the setting of familial adenomatous polyposis (FAP), there have been attempts to identify those at greatest risk for the development of adenocarcinoma of the duodenum. A classification system (the modified Spigelman classification  (<a class="graphic graphic_table graphicRef71691" href="/d/graphic/71691.html" rel="external">table 17</a>)) recognizes five grade scales (stages O to IV) based on the number of polyps (1 to 4, 4 to 20, &gt;20), their size in mm (1 to 4, 5 to 10, and &gt;10), histology (tubular, tubulovillous, villous), and severity of dysplasia (mild, moderate, severe) [<a href="#rid120">120</a>]. Patients with stage IV disease appear to be at the greatest risk for developing adenocarcinoma, leading some authors to recommend prophylactic duodenectomy in this setting, although this is a controversial area. (See  <a class="medical medical_review" href="/d/html/2592.html" rel="external">"Familial adenomatous polyposis: Screening and management of patients and families", section on 'Upper gastrointestinal tumors'</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Leiomyoma</span><span class="headingEndMark"> — </span>Small bowel leiomyomas occur most frequently in the jejunum, and they may reach considerable and even palpable size by the time they are diagnosed  (<a class="graphic graphic_diagnosticimage graphicRef78186" href="/d/graphic/78186.html" rel="external">image 1</a> and <a class="graphic graphic_picture graphicRef60327" href="/d/graphic/60327.html" rel="external">picture 1</a>). Histologically, these tumors are often difficult to distinguish from malignant leiomyosarcomas, although the distinction is important from the standpoint of resection extent.</p><p>Determination of tumor grade may be used to assist in treatment decisions. In a series of 131 patients, for example, a mitotic index (MI) ≥2 (defined as the number of mitoses per 50 high power fields [HPF]) identified a population of patients who benefited from more extensive surgery [<a href="#rid121">121</a>]. Despite conservative resection in 67 percent of these patients, there were no recurrences in those who had a MI &lt;2, compared with 16 percent in patients with a higher MI.</p><p class="headingAnchor" id="H29"><span class="h2">Lipoma</span><span class="headingEndMark"> — </span>Small bowel lipomas can produce many complications, including obscure gastrointestinal bleeding. Lipomas of the small bowel have no malignant potential. Excision is required only if symptomatic; incidentally discovered tumors should be left untreated.</p><p class="headingAnchor" id="H30"><span class="h2">Hamartomas and Peutz-Jeghers syndrome</span><span class="headingEndMark"> — </span>Peutz-Jeghers syndrome is an inherited disorder characterized by mucocutaneous melanotic pigmentation and gastrointestinal polyps. The lesions are hamartomas that occur primarily in the jejunum and ileum. There are few reports of malignant transformation. Surgical treatment is limited to the segment responsible for symptoms [<a href="#rid118">118,122</a>]. (See  <a class="medical medical_review" href="/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H92368095"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119797.html" rel="external">"Society guideline links: Soft tissue sarcoma"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>A variety of malignant (eg, adenocarcinomas, neuroendocrine tumors, gastrointestinal stromal tumors [GISTs] and non-GIST soft tissue sarcomas, and lymphomas) and benign neoplasms (eg, adenomas, leiomyomas, and lipomas) arise within the small bowel. (See  <a class="medical medical_review" href="/d/html/2517.html" rel="external">"Epidemiology, clinical features, and types of small bowel neoplasms"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of a small bowel tumor is often made late in the course of the disease because of their rarity and nonspecificity of symptoms (abdominal pain, weight loss, nausea and vomiting, occult gastrointestinal tract bleeding) (See  <a class="medical medical_review" href="/d/html/2516.html" rel="external">"Diagnosis and staging of small bowel neoplasms"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following represent our approach to treatment for each tumor type:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenocarcinoma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery</strong></p><p></p><p class="bulletIndent2">For localized adenocarcinomas of the second portion of the duodenum, we recommend pancreaticoduodenectomy rather than segmental resection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We suggest segmental resection rather than pancreaticoduodenectomy for lesions in the first, third and fourth portion of the duodenum, if negative resection margins can be achieved (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Duodenal tumors'</a> above.)</p><p></p><p class="bulletIndent2">Adenocarcinomas involving the jejunum or proximal ileum require wide excision of the malignancy and surrounding tissues at risk for contiguous spread. Tumors of the distal ileum require resection of the ileocolic artery and associated regional lymph nodes. (See <a class="local">'Locoregional disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Perioperative therapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For all patients with lymph node-positive, completely resected small bowel adenocarcinoma, we suggest six months of postoperative oxaliplatin-containing adjuvant chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adjuvant therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with node-positive duodenal primaries, we suggest fluoropyrimidine-based chemoradiotherapy in addition to adjuvant oxaliplatin-containing systemic chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Chemoradiotherapy for duodenal primaries'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with completely resected T3 or T4 node-negative resected small bowel adenocarcinomas, observation or six months of adjuvant chemotherapy are both acceptable options, and we base our decision-making on clinicopathologic features, the presence or absence of deficient mismatch repair (dMMR), and patient preference. If adjuvant chemotherapy is chosen for node-negative disease, we suggest a fluoropyrimidine alone (<a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, leucovorin-modulated FU), as long as the tumor has proficient MMR. In the setting of dMMR, we suggest an oxaliplatin-containing regimen rather than a fluoropyrimidine alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adjuvant therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We consider neoadjuvant therapy on a case-by-case basis in patients with bulky or locally advanced disease. (See <a class="local">'Indications for neoadjuvant therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unresectable or metastatic disease</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are able to tolerate it, we suggest systemic chemotherapy rather than supportive care alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We use an oxaliplatin-based chemotherapy regimen as a first-line regimen. (See <a class="local">'Systemic therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hepatic resection is a reasonable option for selected patients with potentially resectable liver metastases, a controlled primary site, and no extrahepatic metastases. (See <a class="local">'Potentially resectable metastases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sarcoma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend en bloc segmental resection with tumor-free margins rather than peritumoral resection as the primary treatment modality for most resectable GISTs and other primary sarcomas of the small bowel (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We suggest initial <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> rather than upfront surgery for a borderline resectable or unresectable but non-metastatic small bowel GIST tumor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Sarcoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risks, benefits, and recommendations regarding the use of adjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> following complete resection of a GIST are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroendocrine tumors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend wide en bloc segmental resection that includes the adjacent mesentery and lymph nodes for small bowel neuroendocrine tumors of any size rather than local excision alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The entire bowel and colon should be evaluated prior to and during any surgical intervention given the high rate of concurrent GI neoplasms. (See <a class="local">'Treatment of locoregional disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphoma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In general, the treatment approach for extranodal involvement of the intestinal tract by a lymphoma generally parallels the treatment approach for that histologic subtype of lymphoma arising in nodal regions. (See  <a class="medical medical_review" href="/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign lesions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Management of benign small bowel lesions must be tailored to their size, number, location, malignant potential, and whether they are symptomatic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For simple tubular adenomas, Brunner gland adenomas, and villous adenomas with no evidence of in situ or invasive malignancy, we recommend endoscopic polypectomy, submucosal resection, or simple local resection rather than more radical resection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We recommend radical resection for villous adenomas containing areas of malignant growth (in situ or invasive) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Adenoma'</a> above.)</p><p></p><p class="bulletIndent2">Recommendations regarding management of duodenal adenomas in patients with familial adenomatous polyposis (FAP) are provided elsewhere. (See  <a class="medical medical_review" href="/d/html/2592.html" rel="external">"Familial adenomatous polyposis: Screening and management of patients and families"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most small bowel leiomyomas we recommend open surgical resection rather than observation due to the difficulty in excluding leiomyosarcoma or a GIST tumor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Leiomyoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For lipomas, we suggest excision only if the lesion is symptomatic (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Lipoma'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Overman MJ, Hu CY, Kopetz S, et al. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol 2012; 19:1439.</a></li><li><a class="nounderline abstract_t">Overman MJ, Hu CY, Wolff RA, Chang GJ. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 2010; 116:5374.</a></li><li><a class="nounderline abstract_t">Wilhelm A, Müller SA, Steffen T, et al. Patients with Adenocarcinoma of the Small Intestine with 9 or More Regional Lymph Nodes Retrieved Have a Higher Rate of Positive Lymph Nodes and Improved Survival. J Gastrointest Surg 2016; 20:401.</a></li><li><a class="nounderline abstract_t">Tran TB, Qadan M, Dua MM, et al. Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma. Surgery 2015; 158:486.</a></li><li class="breakAll">National Comprehensive Cancer Networlk (NCCN) guidelines available online at https://www.nccn.org/professionals/physician_gls/ (Accessed on April 24, 2020).</li><li><a class="nounderline abstract_t">Sohn TA, Lillemoe KD, Cameron JL, et al. Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg 1998; 2:79.</a></li><li><a class="nounderline abstract_t">Lai EC, Doty JE, Irving C, Tompkins RK. Primary adenocarcinoma of the duodenum: analysis of survival. World J Surg 1988; 12:695.</a></li><li><a class="nounderline abstract_t">Onkendi EO, Boostrom SY, Sarr MG, et al. 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. J Gastrointest Surg 2012; 16:682.</a></li><li><a class="nounderline abstract_t">Abrahams NA, Halverson A, Fazio VW, et al. Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum 2002; 45:1496.</a></li><li><a class="nounderline abstract_t">Brücher BL, Stein HJ, Roder JD, et al. New aspects of prognostic factors in adenocarcinomas of the small bowel. Hepatogastroenterology 2001; 48:727.</a></li><li><a class="nounderline abstract_t">Joesting DR, Beart RW Jr, van Heerden JA, Weiland LH. Improving survival in adenocarcinoma of the duodenum. Am J Surg 1981; 141:228.</a></li><li><a class="nounderline abstract_t">Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg 1992; 127:557.</a></li><li><a class="nounderline abstract_t">van Ooijen B, Kalsbeek HL. Carcinoma of the duodenum. Surg Gynecol Obstet 1988; 166:343.</a></li><li><a class="nounderline abstract_t">Kaklamanos IG, Bathe OF, Franceschi D, et al. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg 2000; 179:37.</a></li><li><a class="nounderline abstract_t">Barnes G Jr, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1994; 1:73.</a></li><li><a class="nounderline abstract_t">Meijer LL, Alberga AJ, de Bakker JK, et al. Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2018; 25:2681.</a></li><li><a class="nounderline abstract_t">Bakaeen FG, Murr MM, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg 2000; 135:635.</a></li><li><a class="nounderline abstract_t">Cloyd JM, Norton JA, Visser BC, Poultsides GA. Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases. Ann Surg Oncol 2015; 22:573.</a></li><li><a class="nounderline abstract_t">Ochiai Y, Kato M, Kiguchi Y, et al. Current Status and Challenges of Endoscopic Treatments for Duodenal Tumors. Digestion 2019; 99:21.</a></li><li><a class="nounderline abstract_t">Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101:518.</a></li><li><a class="nounderline abstract_t">Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63.</a></li><li><a class="nounderline abstract_t">Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999; 86:2693.</a></li><li><a class="nounderline abstract_t">Contant CM, Damhuis RA, van Geel AN, et al. Prognostic value of the TNM-classification for small bowel cancer. Hepatogastroenterology 1997; 44:430.</a></li><li><a class="nounderline abstract_t">Young JI, Mongoue-Tchokote S, Wieghard N, et al. Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer. Dis Colon Rectum 2016; 59:306.</a></li><li><a class="nounderline abstract_t">Ouriel K, Adams JT. Adenocarcinoma of the small intestine. Am J Surg 1984; 147:66.</a></li><li><a class="nounderline abstract_t">Adler SN, Lyon DT, Sullivan PD. Adenocarcinoma of the small bowel. Clinical features, similarity to regional enteritis, and analysis of 338 documented cases. Am J Gastroenterol 1982; 77:326.</a></li><li><a class="nounderline abstract_t">Struck A, Howard T, Chiorean EG, et al. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol 2009; 100:144.</a></li><li class="breakAll">American Joint Committee on Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.127.</li><li><a class="nounderline abstract_t">Nicholl MB, Ahuja V, Conway WC, et al. Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol 2010; 17:2728.</a></li><li class="breakAll">SEER Survival Monograph: Cancer Survivor Among Adults: US Seer Program, 1988-2001, Patient and Tumor. Cancers of the esophagus, stomach, and small intestine. NIH Pub No 07-6215, SEER Program; National Cancer Institute, Bethesda, MD 2007.</li><li><a class="nounderline abstract_t">Wu TJ, Yeh CN, Chao TC, et al. Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis. World J Surg 2006; 30:391.</a></li><li><a class="nounderline abstract_t">Zar N, Holmberg L, Wilander E, Rastad J. Survival in small intestinal adenocarcinoma. Eur J Cancer 1996; 32A:2114.</a></li><li><a class="nounderline abstract_t">Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010; 199:797.</a></li><li><a class="nounderline abstract_t">Kelsey CR, Nelson JW, Willett CG, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:1436.</a></li><li><a class="nounderline abstract_t">Rose DM, Hochwald SN, Klimstra DS, Brennan MF. Primary duodenal adenocarcinoma: a ten-year experience with 79 patients. J Am Coll Surg 1996; 183:89.</a></li><li><a class="nounderline abstract_t">Talamonti MS, Goetz LH, Rao S, Joehl RJ. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 2002; 137:564.</a></li><li><a class="nounderline abstract_t">Agrawal S, McCarron EC, Gibbs JF, et al. Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol 2007; 14:2263.</a></li><li><a class="nounderline abstract_t">Bauer RL, Palmer ML, Bauer AM, et al. Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment, and prognosis. Ann Surg Oncol 1994; 1:183.</a></li><li><a class="nounderline abstract_t">Kitahara H, Honma Y, Ueno M, et al. Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD). Jpn J Clin Oncol 2019; 49:287.</a></li><li><a class="nounderline abstract_t">Poultsides GA, Huang LC, Cameron JL, et al. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol 2012; 19:1928.</a></li><li><a class="nounderline abstract_t">Moon YW, Rha SY, Shin SJ, et al. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol 2010; 136:387.</a></li><li><a class="nounderline abstract_t">Swartz MJ, Hughes MA, Frassica DA, et al. Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg 2007; 142:285.</a></li><li><a class="nounderline abstract_t">Ecker BL, McMillan MT, Datta J, et al. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database. Cancer 2017; 123:967.</a></li><li><a class="nounderline abstract_t">Ecker BL, McMillan MT, Datta J, et al. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis. Cancer 2016; 122:693.</a></li><li><a class="nounderline abstract_t">Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 2006; 101:2826.</a></li><li><a class="nounderline abstract_t">Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994; 30:161.</a></li><li><a class="nounderline abstract_t">Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993; 72:2124.</a></li><li><a class="nounderline abstract_t">Onkendi EO, Boostrom SY, Sarr MG, et al. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. J Gastrointest Surg 2012; 16:320.</a></li><li><a class="nounderline abstract_t">Fishman PN, Pond GR, Moore MJ, et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006; 29:225.</a></li><li><a class="nounderline abstract_t">Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007; 19:143.</a></li><li><a class="nounderline abstract_t">Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005; 10:132.</a></li><li><a class="nounderline abstract_t">Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009; 27:2598.</a></li><li><a class="nounderline abstract_t">Zhang L, Wang LY, Deng YM, et al. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. J BUON 2011; 16:689.</a></li><li><a class="nounderline abstract_t">Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 2012; 23:561.</a></li><li><a class="nounderline abstract_t">McWilliams RR, Mahoney MR, Machello BT, et al. Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial. J Clin Oncol 2012; 30S: ASCO #314.</a></li><li><a class="nounderline abstract_t">Overman MJ, Adam L, Raghav K, et al. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 2018; 29:139.</a></li><li class="breakAll">Enzinger PC, Zhu A, Blaszkowsky L, et al. Phase I dose finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients with advanced gastrointestinal malignancies (abstract). Data presented at the 2005 ASCO Gastrointestinal Cancers Symposium, Miami, FL, January 27-29, 2005.</li><li><a class="nounderline abstract_t">Overman MJ, Kopetz S, Wen S, et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008; 113:2038.</a></li><li><a class="nounderline abstract_t">Locher C, Malka D, Boige V, et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005; 69:290.</a></li><li><a class="nounderline abstract_t">Polyzos A, Kouraklis G, Giannopoulos A, et al. Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother 2003; 15:503.</a></li><li><a class="nounderline abstract_t">Crawley C, Ross P, Norman A, et al. The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer 1998; 78:508.</a></li><li><a class="nounderline abstract_t">Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984; 53:23.</a></li><li><a class="nounderline abstract_t">Ono M, Shirao K, Takashima A, et al. Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer 2008; 11:201.</a></li><li><a class="nounderline abstract_t">Suenaga M, Mizunuma N, Chin K, et al. Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today 2009; 39:27.</a></li><li><a class="nounderline abstract_t">Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010; 21:1786.</a></li><li><a class="nounderline abstract_t">Tsushima T, Taguri M, Honma Y, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 2012; 17:1163.</a></li><li><a class="nounderline abstract_t">Zaanan A, Gauthier M, Malka D, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 2011; 117:1422.</a></li><li><a class="nounderline abstract_t">Schrock AB, Devoe CE, McWilliams R, et al. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 2017; 3:1546.</a></li><li><a class="nounderline abstract_t">Adam L, San Lucas FA, Fowler R, et al. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res 2019; 25:641.</a></li><li><a class="nounderline abstract_t">Cabel L, Aparicio T, Bieche I, et al. ERBB3-activating mutations in small bowel adenocarcinomas. JCO Precis Oncol 2018; 2.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Gulhati P, Raghav K, Shroff RT, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 2017; 123:1011.</a></li><li><a class="nounderline abstract_t">Santini D, Fratto ME, Spoto C, et al. Cetuximab in small bowel adenocarcinoma: a new friend? Br J Cancer 2010; 103:1305; author reply 1306.</a></li><li><a class="nounderline abstract_t">Overman MJ, Wolff RA, Wang H. Reply: Cetuximab in small bowel adenocarcinoma: a new friend? BR J Cancer 2010; 103:1306.</a></li><li><a class="nounderline abstract_t">Gulhati P, Raghav K, Shroff R, et al. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist 2018; 23:277.</a></li><li><a class="nounderline abstract_t">Li AY, McCusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev 2019; 81:101911.</a></li><li><a class="nounderline abstract_t">Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022; 23:1261.</a></li><li><a class="nounderline abstract_t">Pedersen KS, Foster NR, Overman MJ, et al. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clin Cancer Res 2021; 27:3641.</a></li><li><a class="nounderline abstract_t">Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357:409.</a></li><li><a class="nounderline abstract_t">Middha S, Zhang L, Nafa K, et al. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precis Oncol 2017; 2017.</a></li><li><a class="nounderline abstract_t">Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38:1.</a></li><li><a class="nounderline abstract_t">Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 2019; 37:286.</a></li><li><a class="nounderline abstract_t">Parikh AR, He Y, Hong TS, et al. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist 2019; 24:1340.</a></li><li><a class="nounderline abstract_t">Hemming AW, Sielaff TD, Gallinger S, et al. Hepatic resection of noncolorectal nonneuroendocrine metastases. Liver Transpl 2000; 6:97.</a></li><li><a class="nounderline abstract_t">Ercolani G, Grazi GL, Ravaioli M, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol 2005; 12:459.</a></li><li><a class="nounderline abstract_t">Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244:524.</a></li><li><a class="nounderline abstract_t">Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110:2484.</a></li><li><a class="nounderline abstract_t">Liu Y, Ishibashi H, Takeshita K, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center. Ann Surg Oncol 2016; 23:1625.</a></li><li><a class="nounderline abstract_t">van Oudheusden TR, Lemmens VE, Braam HJ, et al. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery 2015; 157:1023.</a></li><li><a class="nounderline abstract_t">Liu Y, Yonemura Y, Levine EA, et al. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. Ann Surg Oncol 2018; 25:1184.</a></li><li><a class="nounderline abstract_t">Saxena A, Valle SJ, Liauw W, Morris DL. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma. Anticancer Res 2017; 37:5737.</a></li><li><a class="nounderline abstract_t">Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151.</a></li><li><a class="nounderline abstract_t">Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117:3332.</a></li><li class="breakAll">AJCC Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.181.</li><li><a class="nounderline abstract_t">Kasai Y, Mahuron K, Hirose K, et al. Prognostic impact of a large mesenteric mass &gt;2 cm in ileal neuroendocrine tumors. J Surg Oncol 2019; 120:1311.</a></li><li><a class="nounderline abstract_t">Massironi S, Campana D, Partelli S, et al. Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Ann Surg Oncol 2018; 25:3200.</a></li><li><a class="nounderline abstract_t">Kim MK, Warner RR, Roayaie S, et al. Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol 2013; 31:3776.</a></li><li><a class="nounderline abstract_t">Watzka FM, Fottner C, Miederer M, et al. Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis. World J Surg 2016; 40:749.</a></li><li><a class="nounderline abstract_t">Zhang XF, Wu XN, Tsilimigras DI, et al. Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. J Surg Oncol 2019; 120:1302.</a></li><li><a class="nounderline abstract_t">Welch JP, Malt RA. Management of carcinoid tumors of the gastrointestinal tract. Surg Gynecol Obstet 1977; 145:223.</a></li><li><a class="nounderline abstract_t">Strodel WE, Talpos G, Eckhauser F, Thompson N. Surgical therapy for small-bowel carcinoid tumors. Arch Surg 1983; 118:391.</a></li><li><a class="nounderline abstract_t">Rothmund M, Kisker O. Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994; 55 Suppl 3:86.</a></li><li><a class="nounderline abstract_t">Nikou GC, Lygidakis NJ, Toubanakis C, et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005; 52:731.</a></li><li><a class="nounderline abstract_t">Ito H, Perez A, Brooks DC, et al. Surgical treatment of small bowel cancer: a 20-year single institution experience. J Gastrointest Surg 2003; 7:925.</a></li><li><a class="nounderline abstract_t">Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28:317.</a></li><li><a class="nounderline abstract_t">Akerström G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991; 30:547.</a></li><li><a class="nounderline abstract_t">Landerholm K, Zar N, Andersson RE, et al. Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 2011; 98:1617.</a></li><li><a class="nounderline abstract_t">Zaidi MY, Lopez-Aguiar AG, Dillhoff M, et al. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surg 2019; 154:134.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10:81.</a></li><li><a class="nounderline abstract_t">Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307:1265.</a></li><li><a class="nounderline abstract_t">Giuliano K, Nagarajan N, Canner J, et al. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? J Surg Oncol 2017; 115:351.</a></li><li><a class="nounderline abstract_t">Kadakia SC, Parker A, Canales L. Metastatic tumors to the upper gastrointestinal tract: endoscopic experience. Am J Gastroenterol 1992; 87:1418.</a></li><li><a class="nounderline abstract_t">Richie RE, Reynolds VH, Sawyers JL. Tumor metastases to the small bowel from extra-abdominal sites. South Med J 1973; 66:1383.</a></li><li><a class="nounderline abstract_t">FARMER RG, HAWK WA. METASTATIC TUMORS OF THE SMALL BOWEL. Gastroenterology 1964; 47:496.</a></li><li><a class="nounderline abstract_t">Zollinger RM Jr. Primary neoplasms of the small intestine. Am J Surg 1986; 151:654.</a></li><li><a class="nounderline abstract_t">Desa LA, Bridger J, Grace PA, et al. Primary jejunoileal tumors: a review of 45 cases. World J Surg 1991; 15:81.</a></li><li><a class="nounderline abstract_t">Ashley SW, Wells SA Jr. Tumors of the small intestine. Semin Oncol 1988; 15:116.</a></li><li><a class="nounderline abstract_t">Bjork KJ, Davis CJ, Nagorney DM, Mucha P Jr. Duodenal villous tumors. Arch Surg 1990; 125:961.</a></li><li><a class="nounderline abstract_t">Saurin JC, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22:493.</a></li><li><a class="nounderline abstract_t">Morgan BK, Compton C, Talbert M, et al. Benign smooth muscle tumors of the gastrointestinal tract. A 24-year experience. Ann Surg 1990; 211:63.</a></li><li class="breakAll">Sarr MG, Murr MM. Small intestinal neoplasms. In: Surgery: Scientific Principles and Practice, Greenfield LJ (Ed), Lippincott-Raven, 1997. p.844.</li></ol></div><div id="topicVersionRevision">Topic 2509 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187121" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20715162" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26487334" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Patients with Adenocarcinoma of the Small Intestine with 9 or More Regional Lymph Nodes Retrieved Have a Higher Rate of Positive Lymph Nodes and Improved Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26013988" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26013988" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841972" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adenocarcinoma of the duodenum: factors influencing long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2469256" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Primary adenocarcinoma of the duodenum: analysis of survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22350721" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12432298" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462914" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New aspects of prognostic factors in adenocarcinomas of the small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6257130" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Improving survival in adenocarcinoma of the duodenum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349472" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3353832" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Carcinoma of the duodenum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10737576" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Extent of resection in the management of duodenal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7834432" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary adenocarcinoma of the duodenum: management and survival in 67 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946997" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10843358" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : What prognostic factors are important in duodenal adenocarcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25160736" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30554227" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Current Status and Challenges of Endoscopic Treatments for Duodenal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274064" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106677" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594865" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164514" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prognostic value of the TNM-classification for small bowel cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26953989" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691554" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adenocarcinoma of the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081190" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Adenocarcinoma of the small bowel. Clinical features, similarity to regional enteritis, and analysis of 338 documented cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544358" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544358" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458546" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Small bowel adenocarcinoma: understaged and undertreated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458546" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Small bowel adenocarcinoma: understaged and undertreated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16479330" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9014754" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Survival in small intestinal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609724" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A single-institution experience with 491 cases of small bowel adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17689032" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8696551" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Primary duodenal adenocarcinoma: a ten-year experience with 79 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11982470" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17549572" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Surgical management and outcome in primary adenocarcinoma of the small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842287" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30590606" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167476" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19760196" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17372054" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263387" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26717303" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026561" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Incidence and management of primary malignant small bowel cancers: a well-defined French population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8083109" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8374871" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21956430" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755174" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17355111" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15709215" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164203" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22331723" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22481063" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29069279" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29069279" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759326" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282708" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Combination chemotherapy in advanced small bowel adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598944" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9716035" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6690001" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chemotherapy for primary adenocarcinoma of the small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19132481" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19132464" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Chemotherapy for small-bowel Adenocarcinoma at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223786" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622149" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21425142" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28617917" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Genomic Profiling of Small-Bowel Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30352910" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : ERBB3-activating mutations in small bowel adenocarcinomas</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27859010" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842127" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cetuximab in small bowel adenocarcinoma: a new friend?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Reply: Cetuximab in small bowel adenocarcinoma: a new friend?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29259073" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31715421" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : RET fusions in solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33883178" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28596308" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30211344" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682550" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376427" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31040255" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648585" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hepatic resection of noncolorectal nonneuroendocrine metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886903" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998361" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941009" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26717938" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25818658" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29484565" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28982894" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15719376" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21246527" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21246527" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613999" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prognostic impact of a large mesenteric mass&gt;2 cm in ileal neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30054824" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043726" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26822157" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31680243" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/877842" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Management of carcinoid tumors of the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6830429" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Surgical therapy for small-bowel carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7698543" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15966194" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14592670" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Surgical treatment of small bowel cancer: a 20-year single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7879684" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Surgical management of gastrointestinal carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1854512" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Abdominal surgery in patients with midgut carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21858790" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Survival and prognostic factors in patients with small bowel carcinoid tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383112" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383112" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12075401" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Diagnosis of gastrointestinal stromal tumors: a consensus approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22453568" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27885685" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415098" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Metastatic tumors to the upper gastrointestinal tract: endoscopic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4586467" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Tumor metastases to the small bowel from extra-abdominal sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14226219" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : METASTATIC TUMORS OF THE SMALL BOWEL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2424326" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Primary neoplasms of the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994611" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Primary jejunoileal tumors: a review of 45 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285475" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Tumors of the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2378560" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Duodenal villous tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14752072" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2294846" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Benign smooth muscle tumors of the gastrointestinal tract. A 24-year experience.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
